Vir Biotechnology, Inc. (VIR)

NASDAQ · Pharmaceuticals & Biotech · Biological Products, (No Diagnostic Substances)

Price
$11.50
Day
+5.70%
Market cap
$1.95B

Close 2026-09-22.

The company

Vir Biotechnology, Inc. (including its subsidiaries, referred to as “Vir Bio,” “the Company,” “we,” “our” or “us”) is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Our clinical development pipeline consists of investigational therapies targeting hepatitis delta virus (HDV) and multiple solid tumors. In hepatitis delta, we have initiated our registrational ECLIPSE clinical program evaluating the tobevibart and elebsiran combination in people living with chronic hepatitis delta (CHD). The three randomized, controlled trials (ECLIPSE 1, 2, and 3) are ongoing, with ECLIPSE 1 and 3 completing enrollment ahead of the Company’s expectations. Topline results from ECLIPSE 1 are expected in the fourth quarter of 2026 with topline results from ECLIPSE 2 and 3 expected in the first quarter of 2027. Should the ECLIPSE program yield positive results that support regulatory approval and subsequent commercial launch, we believe the combination has the potential to be a new standard of care for CHD patients, for whom approved treatment options are either limited or unavailable. In oncology, we are advancing three Phase 1 clinical studies of dual-masked T-cell engagers (TCEs): VIR-5500 in patients with Prostate-Specific Membrane Antigen (PSMA)-expressing metastatic castration-resistant prostate cancer (mCRPC); VIR-5818 in patients with HER2-expressing tumors; and VIR-5525 in patients with EGFR-expressing tumors.

By product & service

Institutional holders

Largest positions reported on Form 13F for the quarter ended 2026-06-30, by value.

Insider trades

Open-market buys and sales filed on Form 4, newest first. Grants, option exercises and tax withholding are left out.

Recent filings